Raches Ella

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 438 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella, Siddharth Reddy, Harsh Jogdand et al. · The Lancet Infectious Diseases · 2021 · 365 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, Siddarth Reddy, William C. Blackwelder et al. · The Lancet · 2021 · 362 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

Pragya D. Yadav, Gajanan Sapkal, Priya Abraham et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 137 citations · Full text

Life Sciences, Immunology, Infectious Diseases +9

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Gajanan Sapkal, Pragya D. Yadav, Raches Ella et al. · Journal of Travel Medicine · 2021 · 129 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14